New drug cocktail shows promise in Hard-to-Treat cancers
NCT ID NCT02159989
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, while ziv-aflibercept cuts off the tumor's blood supply. The study is too small to confirm if the combo works, but it lays groundwork for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sapanisertib and ziv-aflibercept
What this could lead to
If it works, this could point toward a new combination treatment for advanced cancers that have stopped responding to standard therapy.
What could go wrong
This is a very early Phase I trial with only 83 people, focused on safety and dosing. It is too small to prove effectiveness, and the drugs may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States